#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab

At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.
Source: Colorectal Cancer 16. 6. 2020

News Documented Cardiovascular Benefit of Empagliflozin in New American Diabetes Treatment Guidelines

Two leading overseas medical professional societies, the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), released new recommendations for diabetes treatment in December 2016. They include information on the reduction of cardiovascular mortality in diabetics treated with empagliflozin (Jardiance).
Source: Diabetes 14. 2. 2020

News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency

Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.
Source: Deficiency of Alpha-1-Antitrypsin 12. 1. 2022

News Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?

Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the renin-angiotensin system possibly being the central mediator of the connection between these diseases. The German study cited below therefore examined whether therapy with AT1 receptor blockers for angiotensin II (ARBs, i.e., sartans) reduces the risk of epilepsy in patients with AH as suggested by animal studies.
Source: Sartans in the Treatment of Hypertension 25. 5. 2023

News Recent Advances in Physiotherapy for Hemophiliacs

Physiotherapy specifically focuses on movement and the movement potential of the individual, with the purpose of restoring or maintaining maximum mobility and functional abilities throughout life. Numerous experiences have shown that physiotherapeutic procedures hold a key position for patients with hemophilia.
Source: Hemophilia with Movement 28. 1. 2021

News Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors

Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the 2nd line after progression on a 1st-generation ALK inhibitor, crizotinib. American scientists in a phase II study focused on the efficacy of brigatinib in the treatment of patients with advanced NSCLC who had progressed on 2nd-generation ALK inhibitors.
Source: Non-Small Cell Lung Cancer 15. 2. 2021

News Transition of Hemophilia A Patients with a History of Coagulation Factor Inhibitor to Emicizumab

During the World Federation of Hemophilia (WFH) conference, held virtually in June 2020, interesting results were presented for patients with Hemophilia A who had a history of FVIII inhibitor and are now using Emicizumab.
Source: Quality Life Even with Hemophilia 3. 8. 2020

News The Role of Probiotics in the Prevention of Childhood Infections

Although common acute respiratory and gastrointestinal infections are a part of childhood, they pose a significant burden on families and the healthcare and social care system. An unexpected role in their prevention can be played by the gut microbiome, specifically its support through certain probiotics. However, it is necessary to choose products supported by clinical studies.
Source: GI, colic and microbiome 11. 2. 2020

News Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma

Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has limited efficacy, achieving low response rates and short-lasting remissions. Moreover, there is no curative therapy modality for advanced stages of CTCL. However, the results of the recently concluded ALCANZA clinical trial indicate the potential of brentuximab vedotin in this indication.
Source: Hematologic Malignancies 4. 1. 2022

News Physiological and Clinical Effect of Romiplostim in the Treatment of ITP

Romiplostim in the treatment of immune thrombocytopenia (ITP) has demonstrated safety and the promise of long-term remission, enabling many pediatric and adult patients to discontinue treatment and maintain a drug-free state.
Source: Immune Thrombocytopenia 11. 10. 2021

News Could candesartan counteract adverse intestinal changes induced by hypertension?

An experimental study published last year was the first to show that administration of candesartan may increase the tightness of epithelial junctions in the intestinal wall and positively affect the composition of the microflora. It expands the knowledge of recently described pathophysiological changes in the gut associated with hypertension.
Source: Sartans in the Treatment of Hypertension 6. 3. 2020

News Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP

What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of patients with immune thrombocytopenia (ITP)? Italian authors conducted a survey using the Delphi method among selected experts to gather answers to this question and recommendations for clinical practice. Here, we briefly summarize the key points of their consensus published last year.
Source: Immune Thrombocytopenia 10. 8. 2022

News Use of Enoxaparin in Patients After Implantation of Left Ventricular Assist Device

Left ventricular assist devices (LVAD) are utilized in patients with end-stage heart failure (HF). Warfarin is typically employed for long-term anticoagulation, but there are no standardized recommendations for anticoagulant therapy during the postoperative period. One option to bridge the time until therapeutic INR is achieved after LVAD implantation is the low molecular weight heparin (LMWH) enoxaparin, which was investigated for its efficacy and safety in this indication by experts from Kansas, USA, cited in the following study.
Source: Thromboprophylaxis 28. 11. 2023

News New Solution for Moderate Incontinence –⁠ Discreet Pull-Up Diaper Pants

The range of products for people with incontinence is constantly expanding –⁠ recent additions include pull-up diaper pants labeled Seni Active Basic and Seni Active Classic.
Source: Incontinence 30. 8. 2022

News Romiplostim in a Pregnant Woman −⁠ Case Report

The following clinical case demonstrates good control of resistant immune thrombocytopenia in a pregnant woman during the administration of romiplostim.
Source: Immune Thrombocytopenia 16. 5. 2022

News Effect of Administering Ferric Carboxymaltose on Quality of Life in Heart Failure Patients

The quality of life in patients with heart failure is significantly reduced. The concurrent occurrence of iron deficiency further exacerbates this situation. The AFFIRM-AHF study evaluated the impact of intravenous administration of ferric carboxymaltose on health-related quality of life (HRQoL) in patients with heart failure who also suffered from iron deficiency.
Source: Iron Deficiency and Anemia 7. 2. 2022

News Options for Tapering TPO-RA in ITP Patients: Practical Experience and Expert Consensus

A recently published British study aims to provide recommendations on tapering TPO-RA in patients with immune thrombocytopenia (ITP) based on existing evidence, survey results of clinical practice among hematologists, and expert consensus.
Source: Immune Thrombocytopenia 25. 10. 2022

News EMPATHY Questionnaire as a Tool for Better Personalization of Levothyroxine Doses in Patients with Primary Hypothyroidism?

The therapy for hypothyroidism consists of substitution with levothyroxine (L-T4). Failure to achieve the target thyrotropin hormone (TSH) level can be due to non-compliance (in 60% of cases) or malabsorption of the drug (in 40%). The aim of the presented Italian study was the validation of the EMPATHY questionnaire for better personalization of therapy.
Source: Thyroid Disorders 25. 10. 2022

News INFOGRAPHIC: Prevention and Management of Hypotension During Sacubitril/Valsartan Treatment

Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension.
Source: Chronic Heart Failure and Lipidology 20. 5. 2021

News Efficacy and Safety of Dupilumab in the Treatment of Severe Asthma Insufficiently Controlled by Standard Therapy –⁠ Current Clinical Practice Data

If severe bronchial asthma with type 2 inflammation is insufficiently controlled by combined maintenance therapy, dupilumab –⁠ a recombinant monoclonal antibody inhibiting the signaling pathway of interleukins 4 and 13 –⁠ can be added. What is its efficacy in clinical practice? We summarize findings from 3 recent retrospective studies.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 16. 3. 2023

News Dabigatran as Effective Prevention of VTE Recurrence Also in Patients with Thrombophilia

With increasing positive experience with direct oral anticoagulants, the question arises of how these drugs work in different groups of patients −⁠ for example, in those who have a congenital or acquired thrombophilic state.
Source: Anticoagulant Treatment 17. 3. 2020

Journal articles Consultation as the main factor affecting the choice of way of using the combined hormonal contraception: comparison of the CHOICE study results

Author of the article: Tomáš Fait Source: Praktická gynekologie | 2-4/2012 30. 10. 2012

News Will up-titration or combination with bisoprolol help to better control hypertension in amlodipine users?

Will patients with hypertension who do not achieve control of this condition with amlodipine at a dose of 5 mg benefit more from up-titration or combining it with bisoprolol? The answer to this question was sought in a study published this year by German authors.
Source: Cardiovascular Continuum 25. 10. 2022

News New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis

Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a closer look at this recently approved drug in our brief summary.
Source: Psoriasis 25. 4. 2022

News ESC 2022: Can Modern Treatment of Acute Heart Failure Improve (Re)hospitalization Prevention?

Heart failure (HF) and the possibilities of its therapy were one of the frequently discussed topics at this year's annual congress of the European Society of Cardiology (ESC 2022), which took place at the end of August in Barcelona. The potential of current approaches in reducing the risk of hospitalization or rehospitalization due to HF was also discussed. In summary, we present the insights from a symposium focused directly on this issue.
Source: Chronic Heart Failure and Lipidology 19. 10. 2022

1 6 7 8 9 10 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#